Novel actions of nonsteroidal anti-inflammatory drugs on vascular ion channels: Accounting for cardiovascular side effects and identifying new therapeutic applications

Lioubov I. Brueggemann, Bharath K. Mani, Alexander R. Mackie, Leanne L. Cribbs, Kenneth L. Byron

Research output: Contribution to journalComment/debate

29 Citations (Scopus)

Abstract

Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used medications for the treatment of both acute and chronic pain. Selective cyclooxygenase-2 (COX-2) inhibitors, such as celecoxib (Celebrex®), rofecoxib (Vioxx®), and diclofenac, have been among the most widely prescribed NSAIDs because they prevent the generation of prostaglandins involved in inflammation and pain, but avoid some of the gastrointestinal complications associated with less selective COX-1/COX-2 inhibitors. In 2004, rofecoxib (Vioxx®) was voluntarily withdrawn from the market because of adverse cardiovascular side effects. This led to an explosion of research into the cardiovascular effects of the 'coxibs', which revealed differential cardiovascular risk profiles among the members of this drug class. The differential risk profiles may relate to the tendency of some of the drugs to elevate blood pressure (BP). An important component of BP regulation is dependent on the contractile state of vascular smooth muscle cells (VSMCs), which is controlled to a large extent by the activities of KCNQ (Kv7 family) potassium channels and L-type calcium channels. Our recently published data indicate that celecoxib, but not rofecoxib or diclofenac, at therapeutically relevant concentrations, acts as a Kv7 potassium channel activator and a calcium channel blocker, causing relaxation of VSMCs and decreasing vascular tone. These vasorelaxant ion channel effects may account for the differential cardiovascular risk profiles among the different COX-2 inhibitors. We further speculate that these properties may be exploited for therapeutic benefit in the treatment of cardiovascular diseases or other medical conditions.

Original languageEnglish (US)
Pages (from-to)15-19
Number of pages5
JournalMolecular and Cellular Pharmacology
Volume2
Issue number1
DOIs
StatePublished - Mar 9 2010

Fingerprint

Celecoxib
Ion Channels
Cyclooxygenase 2 Inhibitors
Blood Vessels
Anti-Inflammatory Agents
Pharmaceutical Preparations
Diclofenac
Potassium Channels
Vascular Smooth Muscle
Smooth Muscle Myocytes
Blood Pressure
Therapeutics
L-Type Calcium Channels
Explosions
Calcium Channel Blockers
Acute Pain
Vasodilator Agents
Chronic Pain
Prostaglandins
Cardiovascular Diseases

Keywords

  • Blood pressure
  • Cardiovascular effects
  • Cyclooxygenase-2 inhibitors
  • Nonsteroidal anti-inflammatory drugs
  • Vascular ion channels

ASJC Scopus subject areas

  • Molecular Biology
  • Pharmaceutical Science

Cite this

Novel actions of nonsteroidal anti-inflammatory drugs on vascular ion channels : Accounting for cardiovascular side effects and identifying new therapeutic applications. / Brueggemann, Lioubov I.; Mani, Bharath K.; Mackie, Alexander R.; Cribbs, Leanne L.; Byron, Kenneth L.

In: Molecular and Cellular Pharmacology, Vol. 2, No. 1, 09.03.2010, p. 15-19.

Research output: Contribution to journalComment/debate

@article{927eb31c1d694f169cb667e80a924880,
title = "Novel actions of nonsteroidal anti-inflammatory drugs on vascular ion channels: Accounting for cardiovascular side effects and identifying new therapeutic applications",
abstract = "Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used medications for the treatment of both acute and chronic pain. Selective cyclooxygenase-2 (COX-2) inhibitors, such as celecoxib (Celebrex{\circledR}), rofecoxib (Vioxx{\circledR}), and diclofenac, have been among the most widely prescribed NSAIDs because they prevent the generation of prostaglandins involved in inflammation and pain, but avoid some of the gastrointestinal complications associated with less selective COX-1/COX-2 inhibitors. In 2004, rofecoxib (Vioxx{\circledR}) was voluntarily withdrawn from the market because of adverse cardiovascular side effects. This led to an explosion of research into the cardiovascular effects of the 'coxibs', which revealed differential cardiovascular risk profiles among the members of this drug class. The differential risk profiles may relate to the tendency of some of the drugs to elevate blood pressure (BP). An important component of BP regulation is dependent on the contractile state of vascular smooth muscle cells (VSMCs), which is controlled to a large extent by the activities of KCNQ (Kv7 family) potassium channels and L-type calcium channels. Our recently published data indicate that celecoxib, but not rofecoxib or diclofenac, at therapeutically relevant concentrations, acts as a Kv7 potassium channel activator and a calcium channel blocker, causing relaxation of VSMCs and decreasing vascular tone. These vasorelaxant ion channel effects may account for the differential cardiovascular risk profiles among the different COX-2 inhibitors. We further speculate that these properties may be exploited for therapeutic benefit in the treatment of cardiovascular diseases or other medical conditions.",
keywords = "Blood pressure, Cardiovascular effects, Cyclooxygenase-2 inhibitors, Nonsteroidal anti-inflammatory drugs, Vascular ion channels",
author = "Brueggemann, {Lioubov I.} and Mani, {Bharath K.} and Mackie, {Alexander R.} and Cribbs, {Leanne L.} and Byron, {Kenneth L.}",
year = "2010",
month = "3",
day = "9",
doi = "10.4255/mcpharmacol.10.03",
language = "English (US)",
volume = "2",
pages = "15--19",
journal = "Molecular and Cellular Pharmacology",
issn = "1938-1247",
publisher = "Lumitext Publishing",
number = "1",

}

TY - JOUR

T1 - Novel actions of nonsteroidal anti-inflammatory drugs on vascular ion channels

T2 - Accounting for cardiovascular side effects and identifying new therapeutic applications

AU - Brueggemann, Lioubov I.

AU - Mani, Bharath K.

AU - Mackie, Alexander R.

AU - Cribbs, Leanne L.

AU - Byron, Kenneth L.

PY - 2010/3/9

Y1 - 2010/3/9

N2 - Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used medications for the treatment of both acute and chronic pain. Selective cyclooxygenase-2 (COX-2) inhibitors, such as celecoxib (Celebrex®), rofecoxib (Vioxx®), and diclofenac, have been among the most widely prescribed NSAIDs because they prevent the generation of prostaglandins involved in inflammation and pain, but avoid some of the gastrointestinal complications associated with less selective COX-1/COX-2 inhibitors. In 2004, rofecoxib (Vioxx®) was voluntarily withdrawn from the market because of adverse cardiovascular side effects. This led to an explosion of research into the cardiovascular effects of the 'coxibs', which revealed differential cardiovascular risk profiles among the members of this drug class. The differential risk profiles may relate to the tendency of some of the drugs to elevate blood pressure (BP). An important component of BP regulation is dependent on the contractile state of vascular smooth muscle cells (VSMCs), which is controlled to a large extent by the activities of KCNQ (Kv7 family) potassium channels and L-type calcium channels. Our recently published data indicate that celecoxib, but not rofecoxib or diclofenac, at therapeutically relevant concentrations, acts as a Kv7 potassium channel activator and a calcium channel blocker, causing relaxation of VSMCs and decreasing vascular tone. These vasorelaxant ion channel effects may account for the differential cardiovascular risk profiles among the different COX-2 inhibitors. We further speculate that these properties may be exploited for therapeutic benefit in the treatment of cardiovascular diseases or other medical conditions.

AB - Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used medications for the treatment of both acute and chronic pain. Selective cyclooxygenase-2 (COX-2) inhibitors, such as celecoxib (Celebrex®), rofecoxib (Vioxx®), and diclofenac, have been among the most widely prescribed NSAIDs because they prevent the generation of prostaglandins involved in inflammation and pain, but avoid some of the gastrointestinal complications associated with less selective COX-1/COX-2 inhibitors. In 2004, rofecoxib (Vioxx®) was voluntarily withdrawn from the market because of adverse cardiovascular side effects. This led to an explosion of research into the cardiovascular effects of the 'coxibs', which revealed differential cardiovascular risk profiles among the members of this drug class. The differential risk profiles may relate to the tendency of some of the drugs to elevate blood pressure (BP). An important component of BP regulation is dependent on the contractile state of vascular smooth muscle cells (VSMCs), which is controlled to a large extent by the activities of KCNQ (Kv7 family) potassium channels and L-type calcium channels. Our recently published data indicate that celecoxib, but not rofecoxib or diclofenac, at therapeutically relevant concentrations, acts as a Kv7 potassium channel activator and a calcium channel blocker, causing relaxation of VSMCs and decreasing vascular tone. These vasorelaxant ion channel effects may account for the differential cardiovascular risk profiles among the different COX-2 inhibitors. We further speculate that these properties may be exploited for therapeutic benefit in the treatment of cardiovascular diseases or other medical conditions.

KW - Blood pressure

KW - Cardiovascular effects

KW - Cyclooxygenase-2 inhibitors

KW - Nonsteroidal anti-inflammatory drugs

KW - Vascular ion channels

UR - http://www.scopus.com/inward/record.url?scp=77953450650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953450650&partnerID=8YFLogxK

U2 - 10.4255/mcpharmacol.10.03

DO - 10.4255/mcpharmacol.10.03

M3 - Comment/debate

AN - SCOPUS:77953450650

VL - 2

SP - 15

EP - 19

JO - Molecular and Cellular Pharmacology

JF - Molecular and Cellular Pharmacology

SN - 1938-1247

IS - 1

ER -